Is Seres Therapeutics going out of business?

Seres Therapeutics, Inc. (MCRB) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Seres Therapeutics, Inc. (MCRB) scores 23 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (10.6% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Fragile

Recent free cash flow is positive, so there is no current cash-burn countdown. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-234.6% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (10.6% YoY) and the capital-structure risk is penalized.
• ROIC: -97.20%
• Filing event risk: Going-Concern Warning (-8 pts)
• Debt / Equity: 1.64x
• Revenue CAGR (3Y): -51.99%
• Cash Runway (years): Self-funded
• Return on Assets: 5.61%
• FCF margin: 109.63%
• Price / Sales: 64.9x (see Valuation)
• Price / Earnings: 9.0x (see Valuation)
• Capital Return: $0 (0% of FCF) Buybacks $0 Dividends $0

Read from filings through 2026-08-05.

Price as of 2026-09-09.